急性低酸素血症性呼吸不全または抜管後不全を伴う非挿管患者における非侵襲的モニタリングを使用した非侵襲的換気サポートの失敗の予測。 PREVISION 研究 (PREVISION)
急性低酸素性呼吸不全または抜管後不全を伴う非挿管患者における非侵襲的モニタリングを使用した非侵襲的換気補助の失敗の予測: PREVISION 研究
The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).
The main question, it aims to answer is:
Does abnormal regional ventilation could predict HFNC or NIV failure?
調査の概要
詳細な説明
This is a single-center, prospective, physiological study.
The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.
The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.
The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.
HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.
The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.
After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M5B 1W8
- St. Michael's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.
説明
Inclusion Criteria:
- Age of ≥ 18 years
- Using NIV or HFNC anywhere in the hospital
Exclusion Criteria:
- Chronic CO2 retention
- Neuromuscular disorder
- Requiring home NIV (CPAP or BIPAP)
- Tracheostomy
- Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Difference in regional ventilation distribution (%)
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diaphragm or parasternal intercostal muscle thickening fraction
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Rapid shallow breathing index (RSBI) in mL/breaths/min
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The intensive care respiratory distress observation scale (IC-RDOS)
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The work of breathing scale
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Self-report of dyspnea visual analog scale (D-VAS)
時間枠:The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。